Quick answer: peptide clinical trial regulation in the U.S. works the same way as for any new drug. A sponsor must file an Investigational New Drug application (IND) under 21 CFR Part 312, wait 30 days unless FDA clears it sooner or imposes a clinical hold, and then test the peptide through Phase 1 (usually 20 to 80 people), Phase 2 (up to several hundred) and Phase 3.[1][3] Most “research peptides” sold online have never entered that process, so their safety and dosing in people are largely unknown.
This guide explains the IND rules, the peptide-specific guidance FDA has issued, and why compounds such as BPC-157 remain outside the trial system. For the wider picture, see our FDA and regulation hub.
What the IND is and when it is required
An IND is the request a sponsor (a company, university or individual investigator) submits to FDA before giving an unapproved drug to people in a U.S. study.[2] The law is section 505(i) of the Federal Food, Drug, and Cosmetic Act, and FDA’s rules are in 21 CFR Part 312.
Under 21 CFR 312.40, an IND goes into effect 30 days after FDA receives it unless FDA notifies the sponsor of a clinical hold, or earlier if FDA says the study can begin.[1] Investigators may not dose anyone until then. Trials must also follow FDA’s informed consent rules (21 CFR Part 50) and institutional review board rules (21 CFR Part 56).
A typical IND contains three kinds of information:[2]
- Animal pharmacology and toxicology data, to show the drug is reasonably safe for first use in people.
- Manufacturing information, including composition, stability and controls, to show the sponsor can make consistent batches.
- Clinical protocols and investigator information, so FDA can judge whether participants face unreasonable risk.
The manufacturing section is where many peptides sold online would fail first. A sponsor has to describe exactly what is in the vial; a “research use only” label is not a specification.
The three phases of a clinical trial
21 CFR 312.21 defines the phases:[3]
| Phase | Purpose | Typical size |
|---|---|---|
| Phase 1 | First use in humans; metabolism, side effects as doses rise, early signs of effect | Generally 20 to 80 people |
| Phase 2 | Controlled studies of effectiveness for a specific condition, plus common short-term risks | Usually no more than several hundred |
| Phase 3 | Expanded trials to judge overall benefit and risk and support labeling | Several hundred to several thousand |
Phases can overlap, and a sponsor may file one IND covering several of them.[3] Approved peptide drugs such as semaglutide, tirzepatide, liraglutide and teriparatide all went through this sequence. A 2021 review counted more than 80 peptide drugs that had reached the market since insulin.[8]
FDA guidance specific to peptides
There is no separate “peptide law.” Peptides are regulated as drugs (or as biologics, if larger than 40 amino acids), but FDA has issued peptide-focused guidance:
- Clinical pharmacology (draft, 2023). FDA’s draft guidance for peptide drug products, docket FDA-2023-D-3391, covers four topics sponsors should address: hepatic impairment, drug-drug interactions, QTc prolongation risk and immunogenicity. It applies to new drug applications under section 505(b) and is non-binding.[4]
- Immunogenicity (final, 2014). FDA’s guidance on therapeutic protein products sets out how to assess whether a product triggers antibodies that could reduce its effect or cause allergic reactions. The peptide draft points sponsors to this framework.[5][4]
- Synthetic generics of rDNA peptides (May 2021, now withdrawn). This guidance explained when a synthetic copy of glucagon, liraglutide, nesiritide, teriparatide or teduglutide could be approved through an abbreviated new drug application (ANDA) instead of a full NDA. The key test was the impurity profile: applicants were to identify every peptide-related impurity at 0.10% or more, and the generic was not to contain any new specified peptide-related impurity above 0.5%, a level FDA said could raise immunogenicity concerns. New impurities at or below 0.5% had to be justified, including data that they did not add sequences with higher affinity for immune (MHC) molecules.[6]
That third guidance has changed. On July 29, 2026, FDA published a Federal Register notice withdrawing the 2021 guidance because it “no longer reflects FDA’s current scientific thinking,” and said it plans to revise and reissue it. The same notice released revised draft product-specific guidances for peptides including semaglutide, tirzepatide, liraglutide, glucagon and teriparatide.[7] If you read older articles describing the 2021 thresholds as current, they are out of date.
Why most research peptides never enter trials
Running an IND program is expensive and slow, and many popular peptides lack a sponsor willing to pay for it. Common reasons include:
- No owner, no incentive. Many older peptides were described decades ago, so a sponsor may not get patent protection or exclusivity to recover costs.
- Missing basic pharmaceutical science. A 2026 review of BPC-157 found no validated pharmaceutical-grade formulation, a plasma half-life of under 30 minutes in preclinical work, and clinical data from fewer than 30 people across three uncontrolled pilot studies.[9]
- The gray market removes demand for trials. When a peptide can be bought as a “research chemical,” there is little pressure on anyone to fund formal studies. See research use only peptides for why that label does not make products legal for human use.
- Stalled programs. A Phase 1 safety and pharmacokinetic study of BPC-157 (as PCO-02) was registered in 2015, but its status is listed as unknown, and no results have been posted.[10]
There are exceptions. A University of Arkansas randomized, placebo-controlled pilot of daily BPC-157 injections after rotator cuff surgery is registered as an FDA-regulated drug study, with 30 participants planned; it was listed as not yet recruiting, with an estimated January 2027 start, as of September 2026.[11] That is how a peptide moves from anecdote toward evidence.
Trials vs compounding vs “research use”
| Pathway | Who oversees it | What it can show |
|---|---|---|
| IND clinical trial | FDA plus an IRB | Whether a peptide is safe and effective for a condition |
| 503A or 503B compounding | State boards and FDA | Nothing about efficacy; it is a way to fill individual prescriptions |
| “Research use only” sales | Nobody, for human use | Nothing; human use is outside the law |
Compounding status is a separate question. In July 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, TB-500, MOTS-c, KPV, Semax, epitalon and emideltide (DSIP) for the 503A bulks list. Our FDA peptide ban 2026 and 503A vs 503B compounding guides track that process. A committee vote is advice to FDA, not trial evidence.
How to read a peptide trial listing
If you find a peptide on ClinicalTrials.gov, check a few fields before drawing conclusions:
- Status: “unknown” or “withdrawn” usually means no usable data.
- Oversight: “FDA-regulated drug: yes” suggests a U.S. IND is involved.
- Sponsor: universities and established drug developers are more likely to publish results; be wary of records from sellers.
- Phase and size: a 20-person Phase 1 can tell you about short-term safety, not whether a peptide works.
You can also follow how the rules evolved in our peptide regulation timeline and see which peptides made it through in our list of approved peptide drugs. If you want to join a trial, our guide to peptide access rights explains how.
This is general information, not legal advice. Rules and guidance change; check FDA’s guidance database for the current version of any document mentioned here.
